TORONTO, Sept. 3, 2020
/CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company")
(TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated
cannabis leader with core operations in Latin America and Europe, announced today that Alvaro Torres, Khiron CEO and Chris Naprawa, Khiron Chairman, will present
live at VirtualInvestorConferences.com on September 10, 2020.
Date: Thursday, September 10,
2020
Time: 4:30 p.m. ET
Registration
link: https://www.virtualinvestorconferences.com/events/event-details/kcsa-cannabis-investor-conference
VirtualInvestorConferences.com is an investor-focused online
conference series that provides an interactive forum for
publicly-traded companies to meet and present directly with
investors.
Attendees of the event will have an opportunity to ask questions
in real time, and an archived webcast will be available after the
event for those who are not able to join the event live on the day
of the conference. Pre-registration is recommended for attendees
who wish to receive updates prior to the event.
Learn more about the event at
www.virtualinvestorconferences.com.
Recent Company Highlights:
- Issued more than 1,500 medical cannabis prescriptions since the
receipt of the authorization to manufacture and commercialize
high-THC medical cannabis in Colombia
- Expanded reach of Khiron's medical cannabis e-learning platform
to UK market through partnership with a clinician-led organization
Medical Cannabis Clinicians Society
- Launched teleconsultation platform to meet essential needs of
its patient network in Colombia
- Delivered first medical cannabis prescriptions for patients
participating in Project Twenty21 in the UK
- Entered the German medical cannabis market signing an agreement
with Nimbus Health for Khiron branded medical cannabis product
import and sales
- Signed a distribution deal for the Kuida CBD cosmeceutical
brand with DNO Group serving the Hong
Kong market
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both low and high THC medical cannabis products. The
Company has presence in Mexico,
Peru, Uruguay, Brazil, UK, Spain and Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage, and patient oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM now
marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-to-present-at-live-investor-conference-on-september-10th-301123478.html
SOURCE Khiron Life Sciences Corp.